Keros presents on myelodysplastic syndromes, myelofibrosis trials

 

• KER-050 (elritercept) achieved durable transfusion independence in lower-risk MDS, including in patients with high transfusion burden
  
• Durable clinical responses were associated with improvements in patient-reported measures of fatigue
• Biomarker data demonstrate that KER-050 treatment has potential to reduce NT-proBNP a measure of cardiac stress
• Preliminary findings from ongoing Phase 2 clinical trial in myelofibrosis demonstrate that KER-050 can not only ameliorate ineffective hematopoiesis and address cytopenias, but also provide broader clinical benefit seen through reduction of spleen size and improved symptoms
• Keros will be hosting a conference call and webcast today, December 11, 2023, at 8:00 a.m. ET

KER-050 was generally well tolerated by the safety population. There was one dose-limiting toxicity reported from a patient in the 1.5mg/kg dose level of the monotherapy arm. The patient had an increase in hemoglobin of at least 2 g/dL, which met protocol criteria for dose reduction at the end of cycle 1. There were no adverse events associated with this event, and the maximum observed hemoglobin remained within normal limits. There were three cases of fatal TEAEs in the trial that were each deemed unrelated to treatment. The most commonly reported TEAEs (in ≥10% of patients) were diarrhea, thrombocytopenia, asthenia (weakness), fatigue and pyrexia (fever). Treatment-related TEAEs were relatively infrequent, most of which were mild to moderate, with two patients experiencing Grade 3 or higher worsening cytopenias. 

Conference Call and Webcast Information

Keros will host a conference call and webcast today, December 11, 2023, at 8:00 a.m. Eastern time, to discuss the additional data from its two ongoing Phase 2 clinical trials of KER-050, one in patients with MDS and one in patients with MF, which was presented at the 65th ASH Annual Meeting and Exposition.

The conference call will be webcast live at: https://event.webcasts.com/starthere.jsp?ei=1645187&tp_key=cad9574144. The live teleconference may be accessed by dialing (877) 407-0309 (domestic) or (201) 389-0853 (international). An archived version of the call will be available in the Investors section of the Keros website at https://ir.kerostx.com/ for 90 days following the conclusion of the call.

https://www.globenewswire.com/news-release/2023/12/11/2793674/0/en/Keros-Therapeutics-Presents-Clinical-Data-from-its-KER-050-Program-at-the-65th-American-Society-of-Hematology-Annual-Meeting-and-Exposition.html